News > News Archive

Positive Results for Clinical Trial of Time Release Medication for Treatment of Levodopa-Induced Dyskinesia


(June 13, 2013) - Adamas Pharmaceuticals, Inc. announced that the Company's Phase 2/3 clinical trial of ADS-5102 (Nurelin™; amantadine HCl extended release) met the study's primary endpoint. This extended-release formulation of amantadine intended for once-nightly administration is being evaluated for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. Read more…

Go to earlier archived stories